Suchergebnisse - "Van Driest, Sara L"

PubPharm (7)

1

Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy

enthalten in: Clinical and translational science | 2022

von Tuteja, S. | Salloum, R. | Elchynski, A. | +26

2

The need for a refined understanding of CYP2D6 in second-generation antipsychotic outcomes in children and adolescents

enthalten in: Pharmacogenomics | 2021

von Rossow, K. | Vaughn, S. | Strawn, J. | +2

3

Variants in ADRB1 and CYP2C9 : Association with Response to Atenolol and Losartan in Marfan Syndrome

enthalten in: The Journal of pediatrics | 2020

von Van Driest, S. | Sleeper, L. | Gelb, B. | +21

4

Molecular and functional characterization of a human frataxin mutation found in hypertrophic cardiomyopathy

enthalten in: Molecular genetics and metabolism | 2005

von Van Driest, S. | Gakh, O. | Ommen, S. | +2

5

Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy

enthalten in: Journal of the American College of Cardiology | 2004

von Van Driest, S. | Vasile, V. | Ommen, S. | +4

CommentIn: J Am Coll Cardiol. 2005 Jul 19;46(2):380-1; author reply 381-2. - PMID 16022973

6

Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy

enthalten in: Journal of the American College of Cardiology | 2004

von Van Driest, S. | Jaeger, M. | Ommen, S. | +4

7

Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy

enthalten in: Circulation | 2002

von Van Driest, S. | Ackerman, M. | Ommen, S. | +5

CommentIn: Circulation. 2003 Jul 29;108(4):e24-5; author reply e24-5. - PMID 12885737

1
[1]